Search is restricted to the following diseases: All diseases
General Information:
Id:
6,261
Diseases:
Glioblastoma
Homo sapiens
article
Reference:
Shabason JE et al.(2011) Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic J. Cell. Mol. Med. 15: 2735-2744
[PMID: 21362133]
Interaction Information:
Comment
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumour. Patients afflicted with this disease unfortunately have a very poor prognosis, and fewer than 5% of patients survive for 5 years from the time of diagnosis. Therefore, improved therapies to treat this disease are sorely needed. One such class of drugs that have generated great enthusiasm for the treatment of numerous malignancies, including GBM, is histone deacetylase (HDAC) inhibitors. Following a comprehensive discussion regarding the risks and benefits of either enrolling in a Phase II clinical trial combining the HDAC inhibitor, valproic acid (VPA), with low-dose temozolomide and radiation, versus the standard of care regimen of low-dose temozolomide and radiation, the patient opted to enroll in the clinical trial. The patient completed the experimental protocol of 6 weeks of concurrent VPA, temozolomide and radiation to a total dose of 60 Gy, with minimal toxicity. She continued with a total of 20 cycles of adjuvant temozolomide. At the time that this patient was presented at the Grand Rounds lecture, it had been approximately 18 months since her last dose of temozolomide and 3.5 years since her initial diagnosis of GBM. The patient remains clinically and radiologically stable with no evidence of disease progression.
CIDeRplus